International Consortium for Blood Pressure (ICBP)

International Consortium for Blood Pressure (ICBP)
Name	International Consortium for Blood Pressure
Abbreviation	ICBP
Formation	2008
Headquarters	Cambridge, United Kingdom
Type	Research consortium
Purpose	Genetic epidemiology of blood pressure and hypertension
Region served	Global
Leader title	Director
Leader name	N/A

International Consortium for Blood Pressure (ICBP) The International Consortium for Blood Pressure (ICBP) is a multinational research collaboration focused on the genetic determinants of blood pressure and hypertension. The consortium aggregates genome-wide association study data from academic institutions, public health institutes, pharmaceutical companies, and biobanks to identify loci associated with systolic and diastolic blood pressure, pulse pressure, and hypertension.

History and formation

ICBP traces origins to meetings of investigators from the Wellcome Trust and Medical Research Council networks alongside representatives from the National Institutes of Health, European Molecular Biology Laboratory, and major university centers such as Harvard University, University of Oxford, University of Cambridge, Stanford University, and Johns Hopkins University. Early collaborators included investigators affiliated with the Framingham Heart Study, the Atherosclerosis Risk in Communities Study, and the EPIC (European Prospective Investigation into Cancer and Nutrition). Founding activities involved coordination with funding bodies including the National Heart, Lung, and Blood Institute, the British Heart Foundation, the European Commission, and philanthropic entities such as the Wellcome Trust. Initial study consortia and coordinating centers engaged population resources like the UK Biobank, the Rotterdam Study, the KORA Study, and the CARDIA (Coronary Artery Risk Development in Young Adults) cohort.

Objectives and scope

ICBP's objectives include discovery of common and rare genetic variants influencing blood pressure, elucidation of biological pathways relevant to cardiovascular phenotypes, and translation of genetic findings into risk prediction and therapeutic targets. The consortium's scope encompasses cross-ancestry meta-analyses involving cohorts from China CDC, Taiwan National Health Research Institutes, Singapore General Hospital, Australian National University, University of Melbourne, Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), and African cohorts coordinated with institutions like the University of Cape Town and the Noguchi Memorial Institute for Medical Research.

Governance and membership

Governance is typically structured around a steering committee with representation from major academic centers such as Imperial College London, Karolinska Institutet, McMaster University, University of Toronto, Peking University, and Seoul National University Hospital. Membership comprises investigators from consortia including the CHARGE Consortium, the GIANT Consortium, the Global Lipids Genetics Consortium, the International HapMap Project contributors, and partners from pharmaceutical research groups like GlaxoSmithKline, Pfizer, and Novartis. Data access and authorship policies were coordinated with ethical oversight from institutional review boards at entities like Mayo Clinic, Cleveland Clinic, and the Karolinska University Hospital.

Major studies and projects

Key projects include large-scale meta-analyses combining GWAS datasets from cohorts such as the Framingham Heart Study, ARIC (Atherosclerosis Risk in Communities), the Cardiovascular Health Study, and the UK Biobank to identify hundreds of blood pressure loci. Collaborative initiatives extended to exome sequencing efforts involving the Exome Aggregation Consortium (ExAC), whole-genome sequencing consortia linked to the 1000 Genomes Project, and multi-ancestry projects allied with the H3Africa Initiative. The consortium contributed to phenotype harmonization efforts aligned with the PhenX Toolkit and to Mendelian randomization analyses using data from the Global Burden of Disease Study and the Million Veteran Program.

Methodology and data resources

ICBP used standardized phenotype definitions harmonized across cohorts like Nurses' Health Study, Health Professionals Follow-up Study, EPIC-Norfolk, and Million Women Study, applying quality control pipelines developed in collaboration with bioinformatics centers such as European Bioinformatics Institute (EBI), Bioinformatics Institute (A*STAR), and the Genome Institute of Singapore. Genotyping arrays from manufacturers like Illumina and Affymetrix were imputed using reference panels from the 1000 Genomes Project, the Haplotype Reference Consortium, and the TOPMed Program. Statistical analysis frameworks incorporated software and methods from developers at Broad Institute, Sanger Institute, University of Michigan Center for Statistical Genetics, and the Wellcome Centre for Human Genetics, employing fixed-effect and random-effect meta-analysis techniques, conditional analyses, and fine-mapping with tools used by the ENIGMA Consortium and the GTEx Project.

Key findings and impact on clinical guidelines

ICBP publications reported discovery of numerous loci influencing systolic blood pressure, diastolic blood pressure, and pulse pressure, implicating pathways involving the renin–angiotensin system, vascular smooth muscle function, and renal sodium handling. Findings intersected with pharmacogenomic targets studied by researchers at Cambridge University Hospitals, Massachusetts General Hospital, Mayo Clinic, and Vanderbilt University Medical Center, informing drug target validation programs at AstraZeneca and Bristol Myers Squibb. Results influenced risk prediction models evaluated against guidelines from the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and national recommendations from agencies such as NICE (National Institute for Health and Care Excellence) and the U.S. Preventive Services Task Force.

Collaborations and partnerships

ICBP maintained partnerships with large repositories and initiatives including the UK Biobank, the International Stroke Genetics Consortium, the CARDIoGRAMplusC4D Consortium, the Global Lipids Genetics Consortium, and the Psychiatric Genomics Consortium for cross-phenotype analyses. Collaborative agreements facilitated data sharing with public health agencies like the Centers for Disease Control and Prevention and international funders such as the European Research Council and the Bill & Melinda Gates Foundation, and research translation partnerships with industry players including Roche, Sanofi, and Bristol-Myers Squibb.

Category:Cardiovascular genetics Category:Genetic epidemiology